Please see full Prescribing Information, including Boxed Warning. Learn about Lo Loestrin® Fe (norethindrone acetate and ethinyl estradiol tablets, ethinyl estradiol tablets and ferrous fumarate tablets). A combination oral contraceptive with the lowest daily dose of estrogen with just 10 mcg.

FOR U.S. HEALTHCARE PROFESSIONALS ONLY

Are you a U.S. healthcare professional?

You are about to enter a site that is for U.S. healthcare professionals only. By selecting “Yes” below, you certify that you are a healthcare professional and that you wish to proceed to the healthcare professionals only site.

You are about to enter a site that is for
U.S. healthcare professionals only. By
selecting “Yes” below, you certify that you
are a healthcare professional and that
you wish to proceed to the healthcare
professionals-only site.

Yes, I am a U.S. healthcare professional

No, I am not a U.S. healthcare professional

INDICATIONS AND USAGE

Taytulla is an estrogen/progestin combination oral contraceptive (COC) indicated for use by females of reproductive age to prevent pregnancy. Efficacy in women with a body mass index (BMI) of more than 35 kg/m² has not been evaluated.

IMPORTANT SAFETY INFORMATION

WARNING: CIGARETTE SMOKING AND SERIOUS CARDIOVASCULAR EVENTS

Cigarette smoking increases the risk of serious cardiovascular events from combination oral contraceptive (COC) use. This risk increases with age, particularly in women over 35 years of age, and with the number of cigarettes smoked. For this reason, COCs should not be used by women who are over 35 years of age and smoke.

Contraindications

Taytulla is contraindicated in pregnant patients, and those with a high risk of arterial or venous thrombotic diseases, liver tumors (benign or malignant) or liver disease, undiagnosed abnormal uterine bleeding, or breast cancer or other estrogen- or progestin-sensitive cancer, now or in the past.

Warnings and Precautions

Discontinue Taytulla if a thrombotic event occurs, and at least 4 weeks before and through 2 weeks after major surgery. Taytulla should not be started any earlier than 4 weeks after delivery, in women who are not breastfeeding. If jaundice occurs, treatment should be discontinued.

Taytulla should not be prescribed for women with uncontrolled hypertension or hypertension with vascular disease. Women who are prediabetic or diabetic, should be monitored while using Taytulla. Alternate contraceptive methods should be considered for women with uncontrolled dyslipidemia. Patients using Taytulla who have a significant change in headaches or irregular bleeding or amenorrhea should be evaluated.

Adverse Reactions

In the clinical trial for Taytulla, the most common adverse reactions (incidence ≥2%) were headache, vaginal candidiasis, nausea, menstrual cramps, breast tenderness, bacterial vaginitis, abnormal cervical smear, acne, mood swings, and weight gain.

Patients should be counseled that COCs do not protect against HIV infection (AIDS) and other sexually transmitted diseases.

Please see full Prescribing Information, including Boxed Warning.

IMPORTANT SAFETY INFORMATION More Less

REFERENCES

Taytulla prescribing information. Irvine, CA: Allergan USA, Inc; 2016.
Data on file. Allergan USA, Inc.
Creinin MD, Keverline S, Meyn LA. How regular is regular? An analysis of menstrual cycle regularity. Contraception. 2004;70(4):289-292.
Aylwin EA, Banbury S, Ferdinando JJC, de Nijs H, inventors; RP Scherer Technologies Inc, assignee. Oral pharmaceutical compositions containing long-chain triglycerides and liphophilic [sic] surfactants. US patent 6,652,880. November 25, 2003.

The oral contraceptive
in a softgel capsule

Is Taytulla right for
your patients?

Bleeding profile^1,2

Incidence of bleeding
and spotting^1,2

Learn about another OC
option with a lower dose
of estrogen

Patient Brochure

Product Samples

Savings Card

The oral contraceptive in a softgel capsule

Is Taytulla right for your patients?

Bleeding profile^1,2

Incidence of bleeding and spotting^1,2

Learn about another OC
option with a lower dose
of estrogen

Patient Brochure

Product Samples

Savings Card

To share valuable information from taytulla.com with a colleague, simply fill in the information below. Your colleague will receive an email with a link to loloestrin.com—along with a notification telling them that you requested it.

Taytulla™ Savings Program

Program Terms, Conditions, and Eligibility Criteria: 1. This offer is good for use only with a valid prescription for Taytulla™ (norethindrone acetate and ethinyl estradiol capsules and ferrous fumarate capsules) at the time the prescription is filled by the pharmacist and dispensed to the patient. 2. Depending on your insurance coverage, most eligible patients pay no more than $25 for each of up to nine (9) one-month prescription fills OR pay no more than $35 for each of up to three (3) three-month prescription fills. Check with your pharmacist for your copay discount. Maximum savings limit applies; patient out-of-pocket expense may vary. 3. This offer is not valid for use by patients enrolled in Medicare, Medicaid, or other federal or state programs (including any state pharmaceutical assistance programs), or private indemnity or HMO insurance plans that reimburse you for the entire cost of your prescription drugs. Patients may not use this offer if they are Medicare-eligible and enrolled in an employer-sponsored health plan or prescription drug benefit program for retirees. This offer is not valid for cash-paying patients. 4. Each card is valid for up to nine (9) prescription fills of a 28-day supply each OR up to three (3) prescription fills of an 84-day supply each. Offer applies only to prescriptions filled before the program expires on 6/30/17. 5. Allergan reserves the right to rescind, revoke, or amend this offer without notice. 6. Offer good only in the USA, including Puerto Rico, at participating retail pharmacies. 7. Void if prohibited by law, taxed, or restricted. 8. This card is not transferable. The selling, purchasing, trading, or counterfeiting of this card is prohibited by law. 9. This card has no cash value and may not be used in combination with any other discount, coupon, rebate, free trial, or similar offer for the specified prescription. 10. This offer is not health insurance. 11. This card expires June 30, 2017. 12. By redeeming this card, you acknowledge that you are an eligible patient and that you understand and agree to comply with the terms and conditions of this offer.

For questions about the program, including savings on mail-order prescriptions, please call 1.855.439.2817.

Pharmacist Instructions for a Patient with an Eligible Third-party Payer: When you redeem this card, you certify that you have not submitted and will not submit a claim for reimbursement under any federal, state, or other government programs for this prescription. Submit the claim to the primary Third-party Payer first, then submit the balance due to Therapy First Plus using BIN #004682 as a Secondary Payer COB with patient responsibility amount and a valid Other Coverage Code (eg, 8). If you receive a rejection due to PA, step-edit, or NDC block, submit Other Coverage Code of 3 (Secondary Claim). The patient’s out-of-pocket expense will be reduced up to the maximum savings limit for the program. Reimbursement will be received from Therapy First Plus. For any questions regarding Therapy First Plus online processing, call the Help Desk at 1.800.422.5604.

Program managed by PSKW, LLC on behalf of Allergan.

Please see full Prescribing Information, including Boxed Warning. Learn about Lo Loestrin® Fe (norethindrone acetate and ethinyl estradiol tablets, ethinyl estradiol tablets and ferrous fumarate tablets). A combination oral contraceptive with the lowest daily dose of estrogen with just 10 mcg.

Are you a U.S. healthcare professional?

INDICATIONS AND USAGE

IMPORTANT SAFETY INFORMATION

Contraindications

Warnings and Precautions

Adverse Reactions

IMPORTANT SAFETY INFORMATION More Less

Share information about Lo Loestrin® Fe

Thank you!

Sorry...

Share information about Lo Loestrin^® Fe